The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer the potential to further optimize visual and anatomical outcomes for patients ...

InflammX Therapeutics has granted Bausch + Lomb an exclusive option to acquire the company, focusing on retinal disease therapies. The acquisition option is contingent upon achieving specified ...

As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy ...

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina ...

Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital and an Outlook Therapeutics Board member, commented, “The 3-month data from NORSE EIGHT provides additional evidence to confirm what ...

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina ...

InflammX Therapeutics, Inc. has entered into an option agreement granting Bausch + Lomb the right to acquire the company. InflammX’s pipeline includes an orally dosed therapeutic candidate targeting ...